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Background: Candida albicans remains as the first cause of nosocomial fungal infections in hospitals worldwide
and its susceptibility pattern should be better described in our tertiary care hospitals.
Methods: This study aimed at identifying the caspofungin susceptibility pattern regarding nosocomial Candida
albicans infection in ten tertiary care hospitals using the methodology proposed by CLSI M27-A3 and CLSI M27-S4,
and its association with risk factors and clinical outcome. The approach involved descriptive research concerning
the diagnosis of nosocomial infection during a 7-month period in 10 hospitals in Bogotá, Colombia. Associations
were established using exact non-parametric statistical tests having a high statistical power (>95%), suitable for small
samples. The exact Mann Whitney test or Kruskall-Wallis non-parametric ANOVA tests were used for distributions which
were different to normal or ordinal variables when comparing three or more groups. Multivariate analysis involved
using binomial, multinomial and ordinal exact logistical regression models (hierarchical) and discrimination power was
evaluated using area under the ROC curve.
Results: 101 nosocomial infections were found in 82,967 discharges, for a Candida spp. infection rate of 12.2 per
10,000 discharges, 30.7% caused by C. albicans, 22.8% by C. tropicalis, 20.8% by C. parapsilosis, 19.8% by other Candida,
3% by C. krusei and 3% by C. glabrata. Statistically significant associations between mortality rate and the absence of
parenteral nutrition were found in multivariate analysis (OR = 39.746: 1.794-880.593 95% CI: p = 0.020). The model’s
predictive power was 83.9%, having an 85.9% significant prediction area (69.5%-100 95% CI; p = 0.001).
Conclusions: Significant differences were found regarding susceptibility results when comparing CLSI M27-A3 to CLSI
M27-S4 when shifting clinical break-point values. However, one nosocomial strain was consistent in having reduced
susceptibility when using both guidelines without having been directly exposed to echinocandins beforehand and
no mutations were found in the FKS1 gene for hot spot 1 and/or hot spot 2 regions, thereby highlighting selective
pressure regarding widespread antifungal use in tertiary healthcare centres. Nutritional conditions and low family
income were seen to have a negative effect on survival rates.
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Candida spp. is the leading opportunistic mycotic agent
worldwide and it is the fourth cause of bloodstream
infections since the 1990s [1,2]. If the rate of mortality
due to nosocomial candidaemia were to be specifically
noted, it would have given a 49% attributable mortality* Correspondence: arley.gomez.lo@gmail.com
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article, unless otherwise stated.rate (38%-60% 95% CI), this being very high for an infec-
tious disease, even surpassing the patients’ base disease
mortality rate [3].
Continuous advances in medical techniques have also
imposed fresh challenges on the management and control
of nosocomial fungal infections [4]. According to reports
collected over a six-and-a-half-year period of epidemio-
logical surveillance at global level by the ARTEMIS study,
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(however, the figures for Colombia are 6.1% for flucona-
zole and 4.0% for voriconazole) [5]. Regarding the echino-
candins, global studies have been found which have not
considered the level of resistance to be significant, given
that echinocandins have only recently been introduced
into clinical practice [6].
The variability in minimum inhibitory concentration
(MIC) (break-points reported in different studies) [6-8],
as well as clinical reports of therapeutic failure in patients
having MIC results of susceptible strains [9,10] have led to
suggesting that break-points for defining susceptibility
against echinocandins should be modified [11]. These
antecedents motivated our group’s interest in determining
nosocomial C. albicans strains’ susceptibility pattern in
tertiary care hospitals in Bogotá, Colombia.
Methods
Study design
This observational study was carried out in ten tertiary
care hospitals (each having between 200 and 500 hos-
pital beds); three of these hospitals admit paediatric
population only, whilst the remaining ones admit the
general population. The nosocomial infection rate was
3.38% in non–ICU wards and 8.26% in ICUs; samples
were collected during seven months, giving a total of
77,763 regular hospital discharges in non-ICU ward and
5,204 ICU discharges. The ICUs were mixed purpose (i.e.
caring for surgical, coronary, septic and poly-traumatised
patients). All cases of nosocomial Candida spp. infection
were reported by infection committees and according to
the CDC definition [12]. Ethics committees from the fol-
lowing institutions approved this study: Clínica del Niño,
Clínica de Occidente, Fundación Cardioinfantil, Hospital
de Kennedy, Fundación Homi-Hospital de la Misericordia,
Hospital del Tunal, Hospital Simón Bolívar, Hospital de la
Samaritana, Clínica Infantil Colsubsidio, Clínica Colsubsidio
Orquídeas and Universidad del Rosario.
All the clinical records were reviewed by each hospi-
tal’s nosocomial infection committee regarding patients
reported as being cases of nosocomial Candida spp.
infection during 7 months and for whom prior culture
results were available. Evident infection 48 hours after
having been admitted to hospital supported by a positive
microbiological culture was defined as a case of nosoco-
mial infection, registered in the clinical record by the
treating physician. The treating physician defined whether
the clinical diagnosis gave either invasive candidiasis or
urinary tract infection by Candida spp. based on clinical
interpretation, laboratory reports and positive cultures
[12]. Clinical records were verified by medical researchers
for all patients and the information was recorded in an
Excel database and Epi Info (version 6.0). All clinical sam-
ples were collected as part of standard patient care andlater managed by a centralised laboratory for verifying
Candida spp. presence.
Antifungal susceptibility test
A broth micro-dilution test (BMD) was carried out at KU
Leuven’s Molecular Cell Biology laboratory according
to the indications given in the CLSI M27-A3 document
[13]. The new recommendations made in CLSI M27-S4
guidelines were incorporated in additional assays; such
assays were carried out in the Corporación de Investi-
gaciones Biológicas (CIB) microbiology laboratory in
Medellín, following all guideline quality and reproducibility
recommendations [14].
Quality control
Quality was controlled according to CLSI indications using
recommended C. krusei ATCC 6258 and C. parapsilosis
ATCC 22019 strains [13].
Antifungal drugs
Caspofungin (Merck), micafungin (Astellas) and flucona-
zole (Sigma) were used in this study. The working solution
for each antifungal drug was prepared in sterile water
following CLSI M27–A3 guidelines, the first two dilutions
in water and the final dilutions in RPMI 1640 solution
adjusted to pH 7.0 with 0.165 M morpholinepropanesulfo-
nic acid (MOPS) buffer [13]. All C. albicans nosocomial
isolates were tested with micafungin dissolved in DMSO,
following CLSI M27-S4 recommendations.
Microorganisms
One hundred and one nosocomial Candida spp. strains
were isolated throughout the study, 31 of them being
nosocomial C. albicans. These isolates were obtained from
the epidemiological surveillance being carried out by
each hospital infection committee and corresponded to
nosocomial infection criteria; each infection recorded
corresponded to an episode per patient.
Identifying the microorganisms
Colombian clinical isolates were initially typed using
manual microbiological systems (API32C and germ tube)
and those classified as being C. albicans were further
confirmed by using MALDI Biotyper RTC software 3.0
(Bruker); the identification spectrum was obtained in
duplicate and compared to the MSP reference spectrum,
simultaneously selected from the BDAL software database
(Bruker) and the CBS–KNAW library. The classification
results obtained by MALDI-TOF-MS (spectrum identifi-
cation cf MSP) led to assigning a score in line with the
equipment’s requirements and classified as follows: firm
identification of genus and specie (≥2.0), reliable identi-
fication of genus (1.7–2.0) and non-reproducible identi-
fication (≤1.7) [15].
Table 1 Demographic and clinical characteristics
Variable ICU n
cases (%)
Non-ICU ward
n cases (%)
Age ≤ 1 year 7 (23%) 1 (3%)
Age ≥ 60 years 5 (16%) 2 (6%)
Male gender 13 (42%) 2 (6%)
Invasive Candidiasis 14 (45%) 4 (13%)
UTI 10 (32%) 3 (10%)
Mortality 7 (23%) 3 (10%)
Broad spectrum AB use 24 (77%) 6 (19%)
CVC 21 (68%) 4 (13%)
Abdominal surgery 6 (19%) 4 (13%)
TPN 15 (48%) 3 (10%)
Immunosuppressant 6 (19%) 0
Length of stay ≥15 days 22 (71%) 5 (16%)
Note: ICU: intensive care unit, UTI: urinary tract infection, AB: antibiotic,
CVC: central venous catheter, TPN: total parenteral nutrition.
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FKS1 gene sequences were amplified using previously
described primers for hot spot (HS) 1 (HS1) and 2 (HS2)
regions: F 5′ GTTCCACCAGTTTATACATTCC 3′ and
5′ ATGTCACTCTTGAGAATTGATC 3′ R for HS1 and
F 5′ GCTCATGAAGCTATCATGTGTT 3′ and 5′ CAA
GACAAACACCTAAACATCC 3′ R for HS2 [10,16]. All
reactions involved using KAPA HiFi containing 0.3 μM of
each primer in a final 25 μL volume. Thermal conditions
were set as follows: denaturing at 95°C for 5 min, followed
by 35 cycles of denaturing at 98°C for 30 seconds, primer
annealing at 54°C for 20 seconds and an extension step at
72°C for 1 min followed by a final extension step at 72°C
for 5 min. Attempts were made to characterise mutations
on at least two different occasions, forming part of two
subsequent biological repetitions; the amplification prod-
ucts were purified by using a Promega Wizard purification
systems kit and then sent for sequencing in both direc-
tions (5′ and 3′) with a BigDye Terminator kit (Macrogen,
Seoul, South Korea).
Statistical analysis
The data was processed using SPSS (version 20.0) and
STATA (version 11.0) software.
Absolute and relative frequency distribution was
expressed as percentages for qualitative variables and
measurements of central tendency, the average and mean
dispersion, the range and standard deviation were used for
quantitative variables. The association of susceptibility and
mortality with different factors, Fisher’s exact test and like-
lihood ratio were evaluated for qualitative variables and
Shapiro Wilk’s test was used for evaluating normality in
normal variables, Student’s T-test for average differences
for independent groups having homogenous or heteroge-
neous variability, using Levene’s test for evaluating the
homogeneity of variance. The exact Mann Whitney test
or Kruskall-Wallis non-parametric ANOVA tests were
used for distributions which were different to normal or
ordinal variables when comparing three or more groups.
Multivariate analysis involved using binomial, multinomial
and ordinal exact logistical regression models (hierarchical)
and discrimination power was evaluated using area under
the ROC curve. Statistical tests were evaluated using 5%
and 10% significance.
Results
Patients’ characteristics
One hundred and one nosocomial Candida spp. infec-
tions were identified during 7 months from 77,763 non-
ICU ward discharges and 5,204 ICU discharges, giving an
incidence rate of 12.2 nosocomial fungaemia per 10,000
discharges; distribution was 30.7% C. albicans, 22.8% C.
tropicalis, 20.8% C. parapsilosis, 19.8% other Candida
spp., 3% C. krusei and 3% C. glabrata. The distribution ofnosocomial C. albicans infection showed that 7 clinical
isolates (13%) came from non-ICU ward discharges and
24 clinical isolates (87%) from ICUs; Table 1 shows the
related clinical characteristics. No significant differences
were found regarding gender distribution (51.6% females
and 48.4% males; p = 1.00, exact binomial test). In age
groups known as being at risk of acquiring infection, 8
patients (26%) aged less than 1 year old and 7 patients
(22%) older than sixty were found. There was 33% mortal-
ity, similar to that described in the literature [3]. Diagnosis
for nosocomial infection caused by Candida spp. had a
similar distribution between invasive candidiasis (58.1%)
and urinary tract infection (41.9%) caused by C. albicans.
Regarding risk factors, more than four broad-spectrum
antibiotics were being used at the same time (10 patients:
32.3%), central venous catheter use (25 patients: 80.6%),
parenteral nutrition (18 patients: 58.1%) and more than
15 days’ hospital length of stay (27 patients: 87%).
Antifungal susceptibility
Table 2 shows MIC values for determining caspofungin
susceptibility following the standardised antifungal sus-
ceptibility test, according to CLSI M27-A3 indications for
the C. albicans group previously identified by MALDI-
TOF-MS. Table 2 also shows the MIC values used for
determining micafungin susceptibility, according to the
new CLSI M27-S4 recommendations. The GV608 strain
was resistant to micafungin following the CLSI M27-S4
guidelines and had previously shown resistance to caspo-
fungin following CLSI M27-A3 guidelines.
Characterising the FKS1 gene mutation pattern
The sequencing results were analysed using CLUSTALW
software and compared to GenBank reference sequences
Table 2 Antifungal susceptibility to caspofungin
according to CLSI M27-A3 and micafungin according to
CLSI M27-S4
Strain MIC CSF MIC MCF
SC5314 ≤0.25 μg/mL (S) ≤0.25 μg/mL (S)
GV475 ≥1 μg/mL (R) ≤0.25 μg/mL (S)
GV78 0.5 μg/mL (I) ≤0.25 μg/mL (S)
GV527 2 μg/mL (R) ≤0.25 μg/mL (S)
GV242 ≥1 μg/mL (R) ≤0.25 μg/mL (S)
GV147 ≥1 μg/mL (R) ≤0.25 μg/mL (S)
GV608 ≥1 μg/mL (R) 0.5 μg/mL (R)
Note: MIC: minimal inhibitory concentration, CSF: caspofungin, MCF: micafungin,
S: susceptible, I: intermediate, R: resistant.
The isolate resistant to both caspofungin and micafungin is shown in bold.
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GV608 nosocomial strain for the aforementioned regions
after analysing both resistant strain sequences.
Statistical association
There was a significant association between mortality
and low socioeconomic level, mortality being greater in
patients having a daily income of less than 9€ (50.0%, 9/
18 cf 15.4%, 2/13) (p = 0.05, Fisher’s exact test). C. albi-
cans infected patients with no parenteral nutrition had a
significant association with mortality when compared to
those having parenteral nutrition (61.8%, 8/13 cf 16.7%,
3/18) (p = 0.014, Fisher’s exact test).
The multivariate exact unconditional logistical regression
model for mortality was significantly associated with the ab-
sence of parenteral nutrition (OR = 39.746: 1.794- 880.593
95% CI; p = 0.020) and closely associated with a background
of being undernourished (p = 0.079, OR = 14.21). The other
factors were not significant (having an abdominal surgery
during hospital stay, the number of antibiotics or length
of hospital stay). The model’s discrimination power
was 83.9% (85.9% area under the ROC curve: 69.5-100
95% CI; p = 0.001).
No statistically significant associations were found be-
tween the susceptibility pattern and the clinical outcomes.
Discussion
The present study explored the C. albicans infection
pattern regarding nosocomial infection and led to char-
acterising susceptibility patterns in a Colombian hospital
setting. This was the first study of its kind to be carried
out in a tertiary care hospital network in Bogotá; it also
explored the echinocandin susceptibility profile as a
recent therapeutic alternative for managing patients at
risk of infection by this fungus. There were differences
between CLSI M27-A3 and CLSI M27-S4 guidelines as the
clinical break-points shifted. CLSI M27-S4 gave less strains
having reduced susceptibility; however, a nosocomial strainwas consistently micafungin-resistant, without having been
directly exposed to echinocandins.
The other relevant findings concerned the clinical asso-
ciations found regarding this type of nosocomial infection,
as well as aspects related to the conditions of patients
requiring nutritional support and having a low monthly
income background, thereby affecting the clinical outcome.
Our study focused on providing a description of Can-
dida spp. nosocomial infection; a high incidence rate of
12.2 cases of infection per 10,000 discharges was revealed
in a representative sample of 10 tertiary care hospitals,
accounting for 82,967 total discharges over a 7-month
period. This finding contrasted with that in the pertinent
literature which referred to nosocomial fungaemia inci-
dence of 4.9 cases of infection per 10,000 discharges [17],
thereby revealing greater nosocomial infection incidence
caused by this microorganism in the sample of hospitals
in Bogotá. Taking the total amount of nosocomial infec-
tions caused by Candida spp., distribution by species
maintained the frequency described in previous studies in
Colombia, where Candida albicans occupied first place
regarding frequency (30.7%) [18]; however, this is the first
report made in Colombia which has evaluated clinical
and microbiological aspects referring to a representative
population involved in nosocomial infection from the 10
tertiary care hospitals which participated in the study.
The echinocandins are currently first-line treatment
agents when managing patients having had previous
exposure to azoles, a report of Candida spp. involving
reduced susceptibility to azoles and/or patients in a critical
or unstable clinical condition [19]. Caspofungin is the
drug of choice for patients having the aforementioned
characteristics; its use is widespread due to it being the
first molecule approved by the FDA [20,21].
According to epidemiological surveillance studies carried
out around the world, excellent levels of activity for echi-
nocandins in vitro have been observed during a six year
follow-up, suggesting that emergent resistance to echino-
candins is hardly likely since the caspofungin inhibition
percentage for C. albicans was 99.6% [22]. However, later
studies have shown the need for re-evaluating the break-
points defining echinocandin susceptibility as clinical
observations have been made regarding therapeutic failure,
in spite of susceptibility tests having indicated lower
than 2 μg/mL values. Such break-points were adjusted
for defining susceptibility as ≤0.25 μg/mL, intermediate
susceptibility as 0.5 μg/mL and ≥1 μg/mL for resistance
[11]. A recent review of clinical break-points proposed
that just ≤0.25 μg/mL should be used for susceptibility
and ≥0.5 μg/mL for resistance [23]. Micafungin or ani-
dulafungin use has recently been proposed instead of
caspofungin in susceptibility tests because of variability
regarding the break-points obtained by several labora-
tories [24]. Caspofungin is the most used antifungal
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in vitro break-points for micafungin regarding patients
being treated with caspofungin thus merits new studies.
Our study revealed differences between both CLSI guide-
lines, indicating that the M27-S4 guideline recommenda-
tions should be followed in new studies. It is worth
stressing that just one nosocomial strain was consistently
micafungin-resistant regarding both methodologies and
had not been previously exposed to echinocandins. It
should be noted that mutations in the FKS1 gene for HS1
and/or HS2, as described in the pertinent literature, were
not found for this nosocomial strain [10]. The foregoing
shows the need for adjusting clinical break-points, as the
susceptibility pattern regarding Candida spp. infections is
dynamic and is influenced by patient and strain exposure
to prolonged treatment with different antifungal drugs
currently available on the market [9,10,25]. Even though
the molecular definition of resistance to echinocandins
has led to identifying punctual mutations in the FKS1
gene [16,20,26], other authors have managed to identify
low susceptibility to echinocandins in the absence of
such mutations [27,28]. The foregoing involves other
mechanisms, meaning that other alternatives could be
considered for explaining the reduced susceptibility
pattern observed in our isolate [27,28]. This C. albicans
strain could have represented a nosocomial infection
transmission pattern where, according to prior reports,
healthcare workers hands represent the main vehicle of
transmission [29].
It is worth noting that this is the first observational
study reported in a population having a higher nosoco-
mial fungal infection rate (12.2/10,000 discharges) than
that reported in pertinent literature (4.9/10,000 discharges
[17]) which highlights the importance of the results here
found, despite the relatively low sample size. However,
associations were established using exact non-parametric
statistical tests having a high statistical power (>95%),
suitable for small sample sizes [30,31] to overcome this
problem.
This is the first study which has evaluated a represen-
tative nosocomial sample of C. albicans infection and
the first aimed at adapting and parametrising the CLSI
M27-S4 guidelines for Colombia. Neither case had a
report of having received prior antifungal treatment and
this also had not been described previously in the litera-
ture; these results reinforce the concept of nosocomial
fungal transmission and the microbiological outcomes
highlight the need of carrying out combination drug
therapy studies in order to minimise resistance risk
[32,33]. Additional microbiological and molecular studies
are required for describing this susceptibility pattern; this
would lead to a better understanding of the mechanisms
facilitating these microorganisms becoming adapted to
exposure to such antifungal drugs.Another relevant aspect concerning studying C. albicans
infection concerns the clinical factors associated with a
risk of contracting the infection [34]. In spite of some
reports having indicated an increase in infections caused
by non-albicans species, C. albicans continues being
responsible for most cases involving fungal infections
in hospitals [35], besides, the associated risk factors
have not changed. The overall description of patients
suffering C. albicans infection in our study has shown
that the presence of central venous catheter, prior broad
spectrum antibiotic use and parenteral nutrition had the
greatest association [36], as well as most patients having
stayed in an ICU.
Regarding the statistical analysis of 31 patients having
nosocomial C. albicans infection, significant associations
were identified which were related to the two most rele-
vant variables: mortality and nutritional condition.
This study revealed an association between mortality
and patients having a daily income of less than 9€, this
being difficult to find in the pertinent literature and
represents an external factor concerning the quality of
hospital care which could affect an outcome which is
unfortunately associated with a particular social condition.
The Colombian healthcare system offers equal coverage to
all population. Associated factors such as the type of insti-
tution or haemodynamic state which could have affected
or been associated with this variable were also explored
but their values were not significant (i.e. the level of
medical treatment was equitable for all patients).
Regarding bivariate analysis of patients infected by C.
albicans, another strongly associated factor referred to
the absence of parenteral nutrition and mortality when
contrasting our study with the literature related to mor-
tality studies. This factor was not specifically mentioned
[3], though references were made to the presence of
parenteral nutrition and a risk of candidaemia [37]. How-
ever, some important work refers to nutritional state and
infection and how compromise regarding nutritional state
favours the risk of infection and even a patient becom-
ing immunocompromised [38]. Multivariate analysis
covering all the risk factors for mortality and candidae-
mia described in different work [3,37] was taken into
account when designing an exact unconditional logis-
tical regression multivariate model which led to finding
a significant association between the absence of parenteral
nutrition. This indicated the relevance of including
patients’ nutritional state and the relevance of including
suitable nutritional support for providing their needs in
a clinical evaluation.
Several studies have been published about nosocomial
Candida spp. infection presentation mode and frequency,
as well as regarding the risk factors associated with the
infection [3,37]; however, little information is available
regarding patients’ susceptibility, socioeconomic conditions
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found in the present study was representative of the
samples taken in the tertiary care hospitals which
participated in the study and was even higher than that
reported in the literature [17]. The relevance of these
results has emphasised aspects regarding prevention
and the rational use of antifungal therapeutic schemes,
expressed by other authors as being one of the best
strategies for controlling this emergent problem [39,40].
Conclusions
Some differences were found regarding susceptibility
results comparing CLSI M27-A3 to CLSI M27-S4 when
shifting clinical break-point values. However, one noso-
comial strain was consistent in having reduced suscepti-
bility when using both guidelines without having been
directly exposed to echinocandins beforehand and had no
mutations in regions previously described for the FKS1
gene, thereby indicating selective pressure concerning
widespread antifungal use in tertiary healthcare centres.
Nutritional conditions and low family income were seen
to have a negative effect on survival rates. The clinical
findings documented regarding the first echinocandin-
resistant nosocomial strain in Colombia which has not
been exposed to this antifungal drug indicate the urgent
need for epidemiological surveillance studies regarding
susceptibility patterns following the latest CLSI M27-S4
recommendations.
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